Published on 22/12/2025
China’s Expanding Role in Global Vaccine Clinical Trials
Introduction
Vaccines have become a strategic priority in China’s public health and global clinical trial agenda. With the National Medical Products Administration (NMPA) modernizing its regulatory framework and China’s participation in International Council for Harmonisation (ICH) guidelines, the country has become a key player in multinational vaccine research. The COVID-19 pandemic further accelerated China’s involvement, as domestic and multinational sponsors conducted trials both within China and across multiple regions. Today, China is not only a site for global vaccine trials but also an innovator, developing vaccines for infectious diseases and cancer immunotherapy. This article explores China’s role in global vaccine trials, including regulatory frameworks, patient recruitment strategies, international collaborations, and challenges that sponsors must navigate.
Background and Regulatory Framework
Evolution of Vaccine Regulations
China’s vaccine oversight has undergone major reforms following high-profile quality incidents. The Vaccine Administration Law, enacted in 2019, established stricter controls on vaccine development, production, and clinical trials. These regulations align with WHO guidelines and emphasize traceability, safety, and transparency.
NMPA Oversight of Vaccine Trials
The NMPA’s Center for Drug Evaluation (CDE) reviews vaccine trial applications and enforces GCP compliance. Vaccine trials often receive priority review due
Case Example: COVID-19 Vaccine Trials
During the COVID-19 pandemic, China played a central role in vaccine development, with multiple candidates advancing through global Phase III trials. These trials highlighted China’s ability to recruit large patient populations quickly and integrate with global MRCTs while complying with evolving regulatory expectations.
Core Clinical Trial Insights
China in Multinational Vaccine Trials
China is now routinely included in global vaccine MRCTs. Early participation ensures diverse patient representation and accelerates access to vaccines for the Chinese population. The NMPA’s alignment with ICH E17 MRCT guidelines has enabled smoother integration of Chinese data into global submissions.
Patient Recruitment and Public Trust
Recruitment for vaccine trials benefits from China’s large population and national mobilization capacity. However, public trust in vaccines remains a sensitive issue due to past quality scandals. Sponsors must implement transparent informed consent processes and engage with communities to build confidence in clinical research.
Data Integrity and Inspections
The NMPA conducts rigorous inspections of vaccine trials, focusing on safety monitoring, data accuracy, and compliance with cold chain management requirements. Electronic data capture systems and validated trial master files (TMFs) are mandatory to ensure integrity.
Role of CROs and Local Partnerships
CROs are instrumental in managing vaccine trials, particularly in coordinating large multicenter studies and ensuring GCP compliance. Partnerships with local hospitals and public health institutions enhance recruitment efficiency and trial oversight.
Pediatric Vaccine Trials
Pediatric vaccine studies face heightened ethical requirements. Parental consent, age-appropriate assent, and additional safety monitoring are mandatory under Chinese regulations. These trials are essential for expanding vaccine coverage in children, a key public health goal.
Integration of Real-World Evidence
The NMPA increasingly encourages the use of real-world evidence (RWE) in vaccine submissions, particularly for post-market safety surveillance. This complements trial data and strengthens regulatory decision-making in line with WHO vaccine monitoring standards.
Best Practices & Preventive Measures
Sponsors should adopt best practices such as engaging early with the NMPA, preparing robust pharmacovigilance systems, and designing culturally appropriate informed consent processes. Including Tier-2 hospitals in vaccine trials expands access to diverse populations. Collaboration with CROs and public health authorities ensures smooth operations and compliance.
Scientific & Regulatory Evidence
China’s vaccine regulatory framework aligns with WHO guidelines, ICH E6(R2) GCP, and EU CTR 536/2014 standards. The Vaccine Administration Law (2019) reinforces transparency and safety, while pharmacovigilance obligations reflect global practices outlined in ICH E2E. Comparative evidence from COVID-19 vaccine MRCTs underscores China’s capacity to contribute high-quality data to global submissions.
Special Considerations
China’s participation in vaccine trials is shaped by data localization laws, which require domestic storage of patient data. Language and cultural diversity across provinces also affect informed consent and trial communication. Sponsors must adapt protocols to accommodate these factors while ensuring regulatory compliance.
When Sponsors Should Seek Regulatory Advice
Sponsors should consult the NMPA early in the design of vaccine trials, especially those involving pediatric populations or new vaccine technologies. Pre-IND and mid-trial consultations clarify expectations for safety monitoring, data management, and eligibility for accelerated review pathways.
Case Studies
Case Study 1: COVID-19 MRCT Participation
A multinational COVID-19 vaccine sponsor included Chinese sites in Phase III trials, enabling rapid recruitment of tens of thousands of participants. Early inclusion led to near-simultaneous approvals in China and other countries, demonstrating the benefits of integrated trial design.
Case Study 2: Pediatric Vaccine Study
A pediatric influenza vaccine trial partnered with Tier-2 hospitals in rural provinces to expand access. With strong CRO support and community engagement, the trial successfully recruited participants while meeting strict ethical requirements. This case illustrates how Tier-2 hospitals can contribute meaningfully to vaccine research.
FAQs
1. Is vaccine trial registration mandatory in China?
Yes, all vaccine trials must be registered in the Chinese Clinical Trial Registry (ChiCTR) and reviewed by the NMPA before initiation.
2. How did China participate in COVID-19 vaccine trials?
China hosted multiple Phase III vaccine trials and collaborated in multinational studies, accelerating both domestic approvals and global submissions.
3. What is the Vaccine Administration Law of 2019?
It is China’s comprehensive framework for vaccine development, trial oversight, production, and post-market surveillance, emphasizing safety and transparency.
4. How are pediatric vaccine trials regulated?
They require parental consent, child assent, and enhanced safety monitoring under NMPA oversight, reflecting global ethical standards.
5. What role do CROs play in vaccine trials?
CROs coordinate site management, patient recruitment, and data monitoring, ensuring compliance with GCP and regulatory expectations.
6. Can vaccine trial data from China be used globally?
Yes, provided it meets ICH and WHO standards. The NMPA’s harmonization with global guidelines supports data acceptance in multinational submissions.
Conclusion & Call-to-Action
China has emerged as a critical player in global vaccine clinical trials, supported by regulatory reforms, infrastructure growth, and integration into multinational studies. While challenges remain in transparency, patient trust, and data localization, the opportunities for sponsors are immense. Organizations planning vaccine trials should prioritize early regulatory engagement, robust pharmacovigilance, and strong local partnerships to ensure both compliance and success. Leveraging China’s unique strengths will be essential in shaping the future of global vaccine development.